Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Equities
US74365A1016
Biotechnology & Medical Research
Sales 2024 * | 74.06M 28.34B 6.17B | Sales 2025 * | 127M 48.73B 10.62B | Capitalization | 84.01M 32.15B 7B |
---|---|---|---|---|---|
Net income 2024 * | 17M 6.51B 1.42B | Net income 2025 * | 70M 26.79B 5.84B | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
5.48
x | P/E ratio 2025 * |
1.42
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.23% |
Latest transcript on Protalix Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30/19/30 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22/19/22 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05/20/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01/19/01 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01/19/01 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01/14/01 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |